施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤

格隆汇
Aug 14
美国FDA已授予百时美施贵宝Zenbexus联合强生Darzalex、hyaluronidase-fihj和地塞米松的加速批准,作为多发性骨髓瘤的二线治疗方案。此次批准基于EXCALIBER-RRMM试验结果,该试验的主要终点为任意时间点达到微小残留病(MRD)阴性的完全缓解。接受iberdomide联合方案治疗的患者MRD阴性完全缓解率为41%,而daratumumab、hyaluronidase-fihj和地塞米松组为21%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10